Many scientific works demonstrate that psilocybin makes it possible to treat diseases such as depression, addictions, or even obsessive compulsive disorders (OCD). Other psychedelic substances with similar effects are also the subject of studies, such as LSD, DMT and mescaline.
In fact, these substances have in common to activate the receptors of a neuromediator in the brain, serotonin, often called the hormone of happiness. They cause a modified state of consciousness for a few hours with hallucinations, a surge of emotions or even a deep introspection that can go as far as mystical experience. And over time, they can block mental rumination (when thoughts are looping in the head in a very unpleasant way).
According to Doctor Benjamin Wyplosz, home hospitalization at home at APHP in Paris, “Psychedelics are the substances classified as the least toxic drugs for the individual and society, and without risk of dependence “. “However, temperate Doctor Lucie Berkovitch, psychiatrist and neuroscience researcher at Saint Anne Hospital in Paris, They can be responsible for mentally difficult experiences, called ‘bad trip’, which can last over time in some patients. “
To minimize this risk, the consumption of psychedelics must be framed medically. In practice, the patient takes only one dose of the substance, then benefits from psychological follow -up. This is called psychotherapy assisted by psychedelic. Generally, beneficial effects begin within 24 hours of taking and last for several months or even years.
In France, the fact that psychedelics are classified as narcotics, in the same way as cocaine or heroin, has limited medical research on these substances. Our country is very late compared to Switzerland or the United States for example. In France, research just begins. The Nîmes University Hospital conducted a study on psilocybin and alcohol dependence last year. Currently, several French centers, including that of Doctor Berkovitch, study the effects of psilocybin on resistant depression. In addition, Doctor Wyplosz is initiated by the Psilonco project, to assess the effects of psilocybin on patients at the end of their life in psychic distress. It is time to change our point of view on the therapeutic use of these substances. Many suffering patients could be relieved.
